New publication describes DiosCURE’s multivalent single-chain antibodies to inactivate SARS-CoV-2
DiosCURE SE announced a publication in
Science describing its core technology of multivalent single-chain antibodies with a unique molecular mode-of-action to inactivate SARS-CoV-2 virions. An international team led by scientists at the University of Bonn developed and characterized the lead candidates, which are exclusively licensed by DiosCURE.
This global pandemic requires an arsenal of therapeutic and preventative tools and our lead candidates will allow us to contribute to what will be an ongoing battle. DiosCURE was established with the goal of developing novel, best-in-class immunotherapies to protect a significant population which will remain at risk, including exposed healthcare workers, immunocompromised patients, non-responders to vaccines and patients experiencing post-acute COVID-19 syndrome. The data now published provides a solid foundation to continue our developm
DiosCURE to Develop Highly Specific Single-Chain Antibodies Against SARS-CoV-2, Lead Candidates Described in Science Publication
Core technology includes promising bivalent single-domain antibodies simultaneously targeting two surface structures of the viral spike protein.
Lead candidates DIOS-202 and DIOS-203 are engineered for high potency and their potential to avoid the emergence of escape mutants.
DIOS-202 and DIOS-203 entered into accelerated development to initiate clinical studies later this year.
DiosCURE Therapeutics SE announced a publication in Science describing its core technology of multivalent single-chain antibodies with a unique molecular mode-of-action to inactivate SARS-CoV-2 virions. An international team led by scientists at the University of Bonn developed and characterized the lead candidates, which are exclusively licensed by DiosCURE.